

1 **Novel *FARS2* variants in patients with early onset encephalopathy with or without epilepsy**  
2 **associated with long survival**

3 Giulia Barcia<sup>1,2</sup>, Marlène Rio<sup>1</sup>, Zahra Assouline<sup>1,2</sup>, Coralie Zangarelli<sup>3</sup>, Charles-Joris Roux<sup>4</sup>,  
4 Pascale de Lonlay<sup>5</sup>, Julie Steffann<sup>1,2,3</sup>, Isabelle Desguerre<sup>6</sup>, Arnold Munnich<sup>1,2,3</sup>, Jean-Paul  
5 Bonnefont<sup>1,2,3</sup>, Nathalie Boddaert<sup>4</sup>, Agnès Rötig<sup>2,3</sup>, Metodi D. Metodiev<sup>3</sup>, Benedetta  
6 Ruzzenente<sup>3‡</sup>

7 <sup>1</sup> Department of Genetics, Necker Enfants Malades Hospital, Paris Descartes-Sorbonne Paris  
8 Cité University, Paris, France.

9 <sup>2</sup> French Reference Center for Mitochondrial Diseases (CARAMMEL).

10 <sup>3</sup> Laboratory for Genetics of Mitochondrial Disorders, UMR U1163, Paris Descartes-Sorbonne  
11 Paris Cité University, Imagine Institute, Paris, France.

12 <sup>4</sup> Department of Pediatric Radiology, INSERM UMR 1163, INSERM U1000, Necker Enfants  
13 Malades Hospital, Imagine Institute, Paris Descartes-Sorbonne Paris Cité University, Paris,  
14 France.

15 <sup>5</sup> Reference Center for Inherited Metabolic Diseases, Necker Enfants Malades Hospital, Imagine  
16 Institute, Paris Descartes University, INEM-1151, G2M, MetabERN, Paris, France.

17 <sup>6</sup> Department of Pediatric Neurology, Necker Enfants Malades Hospital, Paris Descartes  
18 University, Paris, France.

19 <sup>‡</sup>, correspondence: Benedetta Ruzzenente, Imagine Institute, Genetics of Mitochondrial  
20 Disorders, 75015 Paris, France; e-mail: [benedetta.ruzzenente@inserm.fr](mailto:benedetta.ruzzenente@inserm.fr)

21

## 22 **Abstract**

23 Mitochondrial translation is essential for the biogenesis of the mitochondrial oxidative  
24 phosphorylation system (OXPHOS) that synthesizes the bulk of ATP for the cell. Hypomorphic  
25 and loss-of-function variants in either mitochondrial DNA or in nuclear genes that encode  
26 mitochondrial translation factors can result in impaired OXPHOS biogenesis and mitochondrial  
27 diseases with variable clinical presentations.

28 Compound heterozygous or homozygous missense and frameshift variants in the *FARS2* gene,  
29 that encodes the mitochondrial phenylalanyl-tRNA synthetase, are commonly linked to either  
30 early-onset epileptic mitochondrial encephalopathy or spastic paraplegia. Here, we expand the  
31 genetic spectrum of *FARS2*-linked disease with three patients carrying novel compound  
32 heterozygous variants in the *FARS2* gene and presenting with spastic tetraparesis, axial  
33 hypotonia and myoclonic epilepsy in two cases.

## 34 **Introduction**

35 Mitochondria contain their own translation system complete with a mitochondria-specific  
36 ribosome (mitoribosome) and translation factors that function like their cytosolic counterparts.  
37 Intramitochondrial translation of mtDNA-encoded proteins is essential for the biogenesis of four  
38 of the five multiprotein complexes that form the ATP-producing oxidative phosphorylation  
39 system (OXPHOS). Inhibition of mitochondrial translation results in isolated or multiple  
40 OXPHOS deficiencies and mitochondrial disease.

41 *FARS2* (OMIM# 611592) encodes the mitochondrial phenylalanyl-tRNA synthetase (mtPheRS),  
42 which charges mt-tRNA<sup>Phe</sup> with phenylalanine for translation. MtPheRS contains four major  
43 domains: an N-terminal domain, a catalytic domain, a linker region (residues 290–322) and an

44 anticodon-binding domain (ABD). Their complex interactions and conformational changes  
45 enable mtPheRS to function as a monomer during aminoacylation (1, 2). To date, 32 *FARS2*  
46 variants have been linked to two major clinical presentations: a) early-onset epileptic  
47 mitochondrial encephalopathy in about two-thirds of the cases (3-12); and b) spastic paraplegia  
48 (13-15). While the former group has a typically poorer prognosis, the latter is associated with  
49 less severe disease and prolonged survival. MRI studies of patients with early-onset disease often  
50 reveal global brain atrophy, cerebellar and basal ganglia abnormalities. In the second group,  
51 spastic paraplegia is associated with weakness of the lower extremities, spasticity and difficulties  
52 with walking. Intellectual disability/developmental delay may be observed in both groups. Here,  
53 we report the identification of 4 novel missense or frameshift variants in the *FARS2* gene in three  
54 unrelated patients (Pts) presenting with spastic tetraparesis, developmental delay and myoclonic  
55 epilepsy in two cases.

## 56 **Subjects and methods**

57 Informed consent was obtained for all patients in accordance with the Declaration of Helsinki  
58 protocols and approved by local institutional review boards in Paris.

59 Detailed clinical presentations of the patients are shown in Table 1. Briefly, all three patients (Pts  
60 1, 2 and 3) were born to non-consanguineous parents (Figure 1A) and presented with disease  
61 within the first weeks of life. They all had developmental delay and axial hypotonia. Pts 1 and 2  
62 developed spastic quadriplegia. Pts 2 and 3 developed pharmaco-resistant epileptic seizures,  
63 mainly myoclonic and associated with a marked photosensitivity in Pt 2; brain MRI showed  
64 variably severe ventriculomegaly (Pts 1, 2 and 3) and brain-stem and basal ganglia involvement  
65 (Pts 2 and 3) (Figure 1B).

66 Causative variants were identified using a next generation sequencing panel targeting 382 genes  
67 involved in mitochondrial diseases (Pts1 and 3) or whole exome sequencing (Pt 2). The variants  
68 were assessed *in silico* and confirmed by Sanger sequencing as in (16). Segregation analysis  
69 confirmed the presence of the variants in the parents.

70 Skin fibroblast cultures from controls and patients, protein extraction and immunoblotting were  
71 carried out as in (17). MtPheRS antibody was purchased from Proteintech (Manchester, UK,  
72 16436-1-AP). The remaining antisera used here were described previously (17). *In vitro* pulse-  
73 labeling of mtDNA-encoded proteins was carried out in cultured patient fibroblasts as described  
74 in (17).

## 75 **Results**

76 All three patients carried compound heterozygous variants including four missense variants  
77 NM\_001318872.1:c.1256G>A p.(Arg419His), NM\_001318872.1:c.989G>A p.(Arg330His),  
78 NM\_001318872.1:c.1113G>T p.(Leu371Phe) and NM\_001318872.1:c.251A>C p.(His84Pro) all  
79 affecting evolutionary conserved amino acids and predictably pathogenic, and one duplication  
80 NM\_001318872.1:c.1269\_1276dup p.(Ser426\*) (Figure 1A and C, and Supplemental Table S1).  
81 None of these variants, but c.1256G>A, were previously reported in the literature. All newly  
82 identified variants were submitted to ClinVar (Submission ID ).

83 Immunoblotting of whole-cell extracts revealed a decreased abundance of mutant mtPheRS in all  
84 three patients' fibroblasts suggesting a structurally destabilizing role of the identified variants  
85 (Figure 2A). Examination of the abundance of mtDNA and nuclear-encoded OXPHOS proteins  
86 revealed a pattern of changes in their abundance consistent with impaired mitochondrial  
87 translation—decreased abundance of the mtDNA-encoded COXII protein and some, but not all,

88 nuclear-encoded OXPHOS proteins (17), revealing multiple OXPHOS deficiency where CI and  
89 CIV are affected (Figure 2B). Interestingly, unlike COXII, the abundance of the mtDNA-  
90 encoded ATP8 was unchanged, probably because it contains a single phenylalanine whereas  
91 COXII contains ten (Figure 2B). Consistent with the immunoblot analysis above and the  
92 essential role in mtPheRS in mitochondrial translation, *in vitro* pulse labelling of mtDNA-  
93 encoded proteins revealed a general decrease in mitochondrial translation in fibroblasts from all  
94 three patients (Figure 2C). Cumulatively, these data indicate that the newly identified *FARS2*  
95 variants result in a destabilized mtPheRS protein and in an inhibition of mitochondrial  
96 translation.

## 97 **Discussion**

98 Our report expands the genetic spectrum of *FARS2*-linked pathologies with four novel *FARS2*  
99 missense or duplication variants whose causal role was supported by bioinformatics and  
100 biochemical analyses.

101 The clinical presentations of *FARS2*-linked disease fall into two categories: a) early-onset severe  
102 encephalopathy with or without epilepsy or b) spastic paraplegia. The epileptic seizures observed  
103 in *FARS2* patients can have variable features in the different patients including neonatal  
104 multifocal seizures, infantile spasms or myoclonic epilepsy with an onset later in infancy.  
105 Patients with early-onset *FARS2*-linked encephalopathy also present with developmental delay  
106 and may have a wide range of brain abnormalities. Most of the previously reported *FARS2*  
107 patients with an early-onset encephalopathy died before two years of age (3-10, 12) whereas two  
108 patients with juvenile-onset epilepsy died soon after it became refractory (11). The clinical  
109 presentation of the three patients reported here was typical of *FARS2* disease with early-onset  
110 encephalopathy with or without epilepsy, included developmental delay and was associated with

111 a prolonged survival. Pts 2 and 3 developed myoclonic pharmaco-resistant seizures whereas no  
112 seizures were reported for Pt 1. In contrast to most other patients with early-onset epilepsy, Pts 2  
113 and 3 were alive at the age of 16 and 5 years, respectively. Similar finding has been reported for  
114 one other *FARS2* patient who presented with generalized epilepsy at age of 19 months and was  
115 alive at 17 years of age (9) suggesting that early-onset epilepsy can be associated with prolonged  
116 survival.

117 Even though hypomorphic or loss-of-function variants in different mitochondrial tRNA  
118 synthetases consistently result in neurological phenotypes, these are generally not specific to  
119 individual enzymes including *FARS2*—early-onset epilepsy and hereditary spastic paraplegia are  
120 genetically heterogeneous and not necessarily linked to tRNA aminoacylation. Moreover, there  
121 is no apparent correlation between the location of different *FARS2* variants along the mtPheRS  
122 polypeptide and the type, onset and severity of disease as, for example, variants affecting the  
123 catalytic domain are just as likely to cause an epileptic phenotype as variants affecting the ABD  
124 domain. This prevents us from establishing precise genotype-phenotype correlations. Most  
125 likely, the specific structural and functional effects of each variant intersect with the genetic  
126 background to determine the extent to which tRNA<sup>Phe</sup> aminoacylation is impacted in each  
127 individual and the specific clinical presentation in that individual. For example, of the variants  
128 reported here, p.(Arg419His) was previously identified in a patient with pediatric spastic  
129 paraplegia and encephalopathy (18). Like this patient, Pt 1 had a non-fatal disease and did not  
130 present any epileptic phenotype. Although similar, the two phenotypes were not identical, which  
131 may result from the fact that the patient reported by Jou and colleagues was compound  
132 heterozygous for this missense variant and a large deletion whereas Pt 1 is compound  
133 heterozygous for the p.(Arg419His) variant and a frameshift variant whose expression status is

134 unclear. Pt 3 also expressed the p.(Arg419His) variant but deviated from the other two patients in  
135 that he also had epileptic phenotype and white-matter degeneration resulting in a relatively more  
136 severe disease. In this case, the p.(Arg419His) variant is compound heterozygous with another  
137 missense mutant, p.(His84Pro), that may account for the specific phenotype observed in the  
138 patient. Thus, phenotypic differences in these cases may result from different genetic modifiers  
139 and/or the presence of different compound heterozygous *FARS2* variants. Keeping in mind the  
140 small number of patients, it appears that the p.(Arg419His) variant is associated with long  
141 survival with or without epilepsy and white matter abnormalities. In the absence of *in vitro*  
142 activity data, we speculate that even though Arg419 is a structurally-important amino acid, its  
143 exchange to proline results in a semi-functional enzyme in manner similar to that proposed for  
144 p.(Arg419Cys) which resulted in spastic paraplegia and only transient epileptic seizures (13, 19).

145 Our data further expands the genetic spectrum of *FARS2* variants and raises awareness that some  
146 patients may present with early-onset epilepsy and long survival. As many patients with *FARS2*  
147 variants are compound heterozygous for two missense variants it would be interesting to  
148 integrate data from *in vitro* activity assays of individual and combined mutant mtPheRS to  
149 determine to what extent, or if at all, different mutant mtPheRS interact functionally and whether  
150 this could add additional information that can help explain the phenotypic presentations observed  
151 in different patients.

## 152 **Acknowledgements**

153 We thank the patients and their families for participating in this study.

## 154 **Conflict of Interest**

155 The authors have no competing financial interests

156 **Funding**

157 Grant Numbers: AFM-TELETHON, nr. 19876, nr. 22529, nr. 22251; ANR, GENOMIT ANR-  
158 15-RAR3-0012-07

159 **References**

160 1. Klipcan L, Levin I, Kessler N, Moor N, Finarov I, Safro M. The tRNA-induced  
161 conformational activation of human mitochondrial phenylalanyl-tRNA synthetase. *Structure*.  
162 2008;16(7):1095-104.

163 2. Yadavalli SS, Klipcan L, Zozulya A, Banerjee R, Svergun D, Safro M, et al. Large-scale  
164 movement of functional domains facilitates aminoacylation by human mitochondrial  
165 phenylalanyl-tRNA synthetase. *FEBS Lett*. 2009;583(19):3204-8.

166 3. Elo JM, Yadavalli SS, Euro L, Isohanni P, Gotz A, Carroll CJ, et al. Mitochondrial  
167 phenylalanyl-tRNA synthetase mutations underlie fatal infantile Alpers encephalopathy. *Hum*  
168 *Mol Genet*. 2012;21(20):4521-9.

169 4. Shamseldin HE, Alshammari M, Al-Sheddi T, Salih MA, Alkhalidi H, Kentab A, et al.  
170 Genomic analysis of mitochondrial diseases in a consanguineous population reveals novel  
171 candidate disease genes. *J Med Genet*. 2012;49(4):234-41.

172 5. Almalki A, Alston CL, Parker A, Simonic I, Mehta SG, He L, et al. Mutation of the  
173 human mitochondrial phenylalanine-tRNA synthetase causes infantile-onset epilepsy and  
174 cytochrome c oxidase deficiency. *Biochim Biophys Acta*. 2014;1842(1):56-64.

- 175 6. Walker MA, Mohler KP, Hopkins KW, Oakley DH, Sweetser DA, Ibba M, et al. Novel  
176 Compound Heterozygous Mutations Expand the Recognized Phenotypes of FARS2-Linked  
177 Disease. *J Child Neurol.* 2016;31(9):1127-37.
- 178 7. Raviglione F, Conte G, Ghezzi D, Parazzini C, Righini A, Vergaro R, et al. Clinical  
179 findings in a patient with FARS2 mutations and early-infantile-encephalopathy with epilepsy.  
180 *Am J Med Genet A.* 2016;170(11):3004-7.
- 181 8. Cho JS, Kim SH, Kim HY, Chung T, Kim D, Jang S, et al. FARS2 mutation and  
182 epilepsy: Possible link with early-onset epileptic encephalopathy. *Epilepsy Res.* 2017;129:118-  
183 24.
- 184 9. Vantroys E, Larson A, Friederich M, Knight K, Swanson MA, Powell CA, et al. New  
185 insights into the phenotype of FARS2 deficiency. *Mol Genet Metab.* 2017;122(4):172-81.
- 186 10. Almannai M, Wang J, Dai H, El-Hattab AW, Faqeih EA, Saleh MA, et al. FARS2  
187 deficiency; new cases, review of clinical, biochemical, and molecular spectra, and variants  
188 interpretation based on structural, functional, and evolutionary significance. *Mol Genet Metab.*  
189 2018;125(3):281-91.
- 190 11. Chen Z, Zhang Y. A patient with juvenile-onset refractory status epilepticus caused by  
191 two novel compound heterozygous mutations in FARS2 gene. *Int J Neurosci.*  
192 2019;129(11):1094-7.
- 193 12. Ville D, Lesca G, Labalme A, Portes VD, Arzimanoglou A, de Bellescize J. Early-onset  
194 epileptic encephalopathy with migrating focal seizures associated with a FARS2 homozygous  
195 nonsense variant. *Epileptic Disord.* 2020;22(3):327-35.

- 196 13. Vernon HJ, McClellan R, Batista DA, Naidu S. Mutations in FARS2 and non-fatal  
197 mitochondrial dysfunction in two siblings. *Am J Med Genet A*. 2015;167A(5):1147-51.
- 198 14. Yang Y, Liu W, Fang Z, Shi J, Che F, He C, et al. A Newly Identified Missense Mutation  
199 in FARS2 Causes Autosomal-Recessive Spastic Paraplegia. *Hum Mutat*. 2016;37(2):165-9.
- 200 15. Sahai SK, Steiner RE, Au MG, Graham JM, Salamon N, Ibba M, et al. FARS2 mutations  
201 presenting with pure spastic paraplegia and lesions of the dentate nuclei. *Ann Clin Transl Neurol*.  
202 2018;5(9):1128-33.
- 203 16. Barcia G, Rio M, Assouline Z, Zangarelli C, Gueguen N, Dumas VD, et al. Clinical,  
204 neuroimaging and biochemical findings in patients and patient fibroblasts expressing ten novel  
205 GFM1 mutations. *Hum Mutat*. 2019.
- 206 17. Ruzzenente B, Assouline Z, Barcia G, Rio M, Boddaert N, Munnich A, et al. Inhibition  
207 of mitochondrial translation in fibroblasts from a patient expressing the KARS p.(Pro228Leu)  
208 variant and presenting with sensorineural deafness, developmental delay, and lactic acidosis.  
209 *Hum Mutat*. 2018;39(12):2047-59.
- 210 18. Jou C, Ortigoza-Escobar JD, O'Callaghan MM, Nascimento A, Darling A, Pias-Peleiteiro  
211 L, et al. Muscle Involvement in a Large Cohort of Pediatric Patients with Genetic Diagnosis of  
212 Mitochondrial Disease. *J Clin Med*. 2019;8(1).
- 213 19. Kartvelishvili E, Tworowski D, Vernon H, Moor N, Wang J, Wong LJ, et al. Kinetic and  
214 structural changes in HsmtPheRS, induced by pathogenic mutations in human FARS2. *Protein*  
215 *Sci*. 2017;26(8):1505-16.
- 216

217 **Table 1. Clinical characterization of Pts1, 2 and 3.**

Patient, sex, origin, age at the follow-up	FARS2 variants	Clinical summary at onset and during follow-up	Brain MRI	Biochemistry
<b>Pt1</b> , Female, French and Chinese origin 8 years	Compound heterozygous c.[1256G>A]; [1269_1276dup] p.(Arg419His); (Ser426*)	Regular pregnancy. BW: 2,471g (<5th percentile), BL: 44.5 cm (<5th percentile); BHC: 32.5cm (<5th percentile); Apgar score 7-9. Presentation < 1 month with axial hypotonia and developmental delay; Head control was acquired at 10 months and she could sit at 2 years. No signs of liver failure. No epileptic seizures. EEG recording (repeated during the follow-up): normal background activity and physiological organization during sleep and wakefulness. Electromyography and nerve conduction were normal. At 8 years: spastic tetraparesis, dystonic movements, and axial hypotonia. Unable to walk unassisted. Dysarthric language, able to write using a keyboard. No psychomotor regression episodes, but stagnation periods concomitant with febrile episodes during the first 3 years of life.	Normal at 1 and 2.2 years  Mild ventriculomegaly, no enlargement of the subarachnoid spaces (3.5 years)	Transient increase in PL: 1.4-2.9 mmol/l (normal range 0.7-1.8) PP: 0.12-0.15 mmol/l (normal range 0.08-0.17) Lactate/pyruvate ratio: 16-19 (normal range 6-14)  OXPHOS: ↓CI in muscle ↓CI+IV in fibroblasts
<b>Pt2</b> , Female, French origin, 16 years	Compound heterozygous c.[989G>A]; [1113G>T] p.(Arg330His); (Leu371Phe)	Regular pregnancy. Normal growth parameters at birth; Apgar score 10/10. 6 weeks: neurological distress, global hypotonia. No signs of liver failure. Severe psychomotor delay. No head control. No visual contact. Can react to auditive stimuli. From 19 months, started to present myoclonic focal and generalized seizures that were resistant to antiepileptic treatment composed by phenytoin, vigabatrin, topiramate, lamotrigine, and clonazepam in variable combinations. EEG showed spikes and poly-spikes discharges predominating on occipital regions, activated by intermittent photic stimulation (IPS). At 16 years: spastic tetraparesis and severe muscular atrophy predominating on inferior limbs. Mild scoliosis.	Marked ventriculomegaly, enlargement of the subarachnoid spaces due to white matter loss, especially in the sylvian fissures, abnormal T2 hyperintensities in the lentiform nuclei and dorsal brainstem (4 months, 15 years), cerebellar atrophy. Proton MR spectrum from the basal ganglia shows elevated lactates (15 years).	PL 2.5-4.8 mmol/l (<2.20 mmol/l) PP: 0.21 mmol/l (normal range 0.08-0.17) Lactate/pyruvate ratio: 13.7-16.6 (normal range 6-14) CSF -L: 9.3 mmol/l (normal range: 1.4-2.2)  OXPHOS: ↓CIV in muscle and fibroblasts
<b>Pt3</b> , Male, French origin, 5 years	Compound heterozygous c.[1256G>A]; [251A>C] p.(Arg419His); (His84Pro)	Regular pregnancy. Normal growth parameters at birth; Apgar score: 10/10. Global hypotonia since birth. No signs of liver failure. Severe psychomotor delay. Partial head control at 10 months. Myoclonic generalized and focal seizures since the first year of life that were partially controlled by levetiracetam, clonazepam and piracetam. EEG showed spikes and poly-spikes discharges predominating on occipital regions. At 5 years: global hypotonia and lumbar mild scoliosis. He cannot sit unaided, has good contact, but no verbal language. He has nasogastric feeding.	Moderate ventriculomegaly and enlargement of the subarachnoid spaces. Dentate nuclei, brainstem, and pallidal T2 hyperintensity at the age of 1 and 3 years. Normal spectroscopy.	PL: 2.6-4.8mmol/l (normal range 0.7-1.8) PP: 7.8 mmol/l (normal range 0.08-0.17) CSF-L: 5.8mmol/l (normal range: 1.4-2.2) Normal liver enzymes  OXPHOS: ↓CIV in fibroblasts

218 Accession numbers: FARS2 cDNA: NM\_001318872.1; mPheRS: NP\_001305801.1. The normal ranges for the different biochemical indicators are indicated in the brackets.

219 List of abbreviation: BW, birth weigh; BL, birth length; BHC, birth head circumference; CSF-L, lactate in cerebral-spinal fluid; PL, plasma lactate; PP, plasma pyruvate.

220 **Figure legends**

221 **Figure 1. Family pedigrees, neuroimaging findings in patients carrying *FARS2* variants**  
222 **and evolutionary conservation of the amino acids affected by these variants** (A) Segregation  
223 of the newly identified *FARS2* variants into the pedigrees of the three reported families. (B)  
224 Axial T2-weighted images showing mild ventriculomegaly, no enlargement of the subarachnoid  
225 spaces in Pt 1; marked ventriculomegaly, enlargement of the subarachnoid spaces due to white  
226 matter loss, especially in the sylvian fissures, abnormal T2 hyperintensities in the lentiform  
227 nuclei and dorsal brainstem in Pt 2; moderate ventriculomegaly and enlargement of the  
228 subarachnoid spaces in Pt 3. (C) Linear map of the mtPheRS protein indicating its domain  
229 organization and position of the identified variants. Previously reported variants are shown above  
230 the mtPheRS map whereas variants reported here are below. *FARS2* variants found in patients  
231 with hereditary spastic paraplegia are indicated with filled square. Evolutionary conservation of  
232 the amino acids affected by the newly described missense variants is shown in a multisequence  
233 alignment of mtPheRS proteins from different species.

234 **Figure 2. Decreased abundance of mtPheRS protein and an impaired mitochondrial**  
235 **translation in patient fibroblasts expressing different *FARS2* variants** (A) Immunoblot  
236 analysis of whole-cell extracts from control (C1 and C2) and patient (Pt 1, Pt 2, Pt 3) fibroblasts  
237 showing decreased abundance of mtPheRS.  $\beta$ -actin was used as a loading control. (B)  
238 Immunoblot analysis of whole-cell extracts from control (C1 and C2) and patient (Pt 1, Pt 2, Pt  
239 3) fibroblasts showing decreased abundance of mtDNA-encoded COXII (OXPHOS complex IV)  
240 and nuclear-encoded NDUFA13 (OXPHOS complex I) and COXIV (OXPHOS complex IV).  
241 Abundance of SDHA (OXPHOS complex II), ATP5A (OXPHOS complex V) and the mtDNA-  
242 encoded subunit ATP8 was unchanged.  $\beta$ -actin was used as a loading control. (C) Pulse-labeling

243 of mtDNA-encoded proteins in control (C1 and C2) and patient (Pt 1, Pt 2, Pt 3) fibroblasts  
244 reveals an inhibition of mitochondrial translation in patient fibroblasts. Coomassie staining was  
245 used to assess loading. A representative of two independent experiments is shown.

246




Figure 1




**A****B****C**

Figure 2